What Ultracet Treats: Main Uses and Benefits

The medication is generally used to provide supportive symptomatic relief for symptoms related to physical discomfort that have reached a moderate intensity or are moderately severe. This combination analgesic is considered relevant when supportive symptom management is appropriate, such as in situations where previous symptom management was not adequate or when additional symptomatic support is needed. It is applied when symptoms create noticeable interference with daily functioning, contributing to easing the overall symptom load.

The medication is commonly used during acute symptomatic episodes, such as short-term pain following an injury, or for relief in post-procedural contexts like after complex dental work or minor surgery. It also may assist with managing symptoms that become more disruptive during flare-ups associated with conditions such as osteoarthritis and certain forms of chronic low back pain. It helps address symptoms that create noticeable physiological strain, offering supportive relief, and may help patients cope more steadily with symptom fluctuations.

“The medication is applied in addressing moderate to moderately severe pain that may interfere with daily functioning.”

Quick Fact: Relief for Disruptive Discomfort

Regulatory References

1. Official ULTRACET Label (via NIH DailyMed)

Ultracet's eligibility for use is strictly defined by government regulatory documentation, focusing on absolute contraindications and population-specific restrictions. The medicine is primarily intended for adults and adolescents 12 years and older whose pain requires this specific combination.

Absolute Contraindications

Ultracet must not be used by patients who have a known hypersensitivity to its active ingredients or other opioids. It is strictly contraindicated in individuals with severe hepatic impairment, those with significant respiratory depression, or patients with a known gastrointestinal obstruction. Use is also prohibited for patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their withdrawal, or those in a state of acute intoxication with alcohol or psychotropic medicines.

Age and Condition Restrictions

Regulatory labeling dictates that the medicine is contraindicated in all children younger than 12 years of age, and in adolescents under 18 following tonsillectomy or adenoidectomy. The medicine is not recommended for women who are pregnant or breastfeeding, as prolonged use during pregnancy may result in neonatal opioid withdrawal syndrome. Patients with severe renal impairment or a history of epilepsy or seizure risk are subject to restricted or conditional use, as specified in the official labeling.

Interactions with other medicines and products

Ultracet, a combination analgesic, has officially documented interaction patterns primarily involving pharmacodynamic effects and metabolic pathways. All information presented is based strictly on government regulatory documents.

Contraindicated Combinations

The co-administration of Monoamine Oxidase Inhibitors (MAOIs), or use within 14 days of their discontinuation, is strictly contraindicated due to the high risk of Serotonin Syndrome and seizures. Co-administration with any other medicinal product containing Tramadol or Acetaminophen is also contraindicated to prevent overdose and associated toxicities.

Documented Pharmacodynamic and Metabolic Interactions

Concomitant use with Central Nervous System (CNS) Depressants (including alcohol) carries a significant risk of profound sedation and respiratory depression. Similarly, combining with other Serotonergic drugs may increase the risk of both Serotonin Syndrome and seizures. The metabolism of the Tramadol component is officially mediated by CYP2D6 and CYP3A4 enzymes; therefore, co-administration with inhibitors or inducers of these enzymes may alter the plasma concentrations of Tramadol and its active metabolite, requiring careful regulatory consideration. Additionally, co-administration with warfarin-like compounds requires periodic evaluation of Prothrombin Time/INR due to reports of altered coagulation markers related to the Acetaminophen component. The medication is also contraindicated in severe hepatic impairment due to the Acetaminophen component.

Ultracet is a fixed-dose combination product containing tramadol hydrochloride and acetaminophen, which modulate distinct pathways to affect signal transmission. Tramadol acts through two primary mechanisms. First, it functions as a non-selective, weak agonist of the mu-opioid receptor (mu-OR), a G-protein coupled receptor. mu-OR binding inhibits adenylyl cyclase activity, leading to ion channel conductance changes and altered presynaptic neurotransmitter release. Second, tramadol inhibits the neuronal reuptake of both norepinephrine (NE) and serotonin (5-HT) in the central descending inhibitory pathways. Acetaminophen exerts its effects primarily through central inhibition of cyclooxygenase (COX) enzymes, particularly COX-2. This inhibition disrupts the production of prostaglandins from arachidonic acid within the central nervous system. The convergent effects of these two agents modulate central nociceptive processing.

Official Administration Guidelines

Ultracet is a fixed-dose combination product containing tramadol and acetaminophen that is intended for oral administration as an immediate-release tablet. The medication is indicated for short-term use, restricted to a maximum duration of five days or less.

Dosage and Schedule

Administration is structured on an as-needed (PRN) basis. The standard initial adult dose is two tablets.

Additional doses may be taken every four to six hours as needed for pain relief, provided the interval between doses is not less than six hours. The total consumption must not exceed 8 tablets (equivalent to 300 mg of tramadol and 2,600 mg of acetaminophen) in any 24-hour period.

Tablets must be swallowed whole with liquid and should not be broken, crushed, or chewed. They may be taken independently of meals.

Population-Specific Constraints

Specific dosage modifications are required for certain populations to prevent potential accumulation of the components:

• Severe Renal Impairment (Creatinine Clearance <30 mL/min): The dose must not exceed two tablets every 12 hours.
• Severe Hepatic Impairment: The medication should not be administered.
• Pediatric Use: The safe and effective use of Ultracet has not been established in children under 12 years of age, and its use is prohibited in this population.
• Discontinuation: If physical dependence is possible following use, the drug requires a gradual downward taper and must not be stopped abruptly.

Due to the combination of active ingredients, Ultracet must not be co-administered with any other products containing tramadol or acetaminophen to avoid exceeding maximum daily limits.

Research Evidence / Overview of Studies for Ultracet

The clinical evaluation of the Tramadol/Acetaminophen combination focused on the study of pain symptoms in both acute and chronic clinical settings. The findings are based primarily on Randomized Controlled Trials (RCTs) and systematic reviews, which contribute to understanding symptom patterns observed in defined study groups and what aspects of how symptoms change remain outside the scope of current research.

Evidence for Use in Acute Pain Management

The research for acute, moderate to moderately severe pain relied heavily on short-term, placebo-controlled trials and subsequent meta-analyses. These studies focused on adult patients with pain following procedures, such as dental surgery, or during acute episodes, such as migraine headaches. Researchers monitored how symptoms changed over time by measuring pain intensity on standardized scales and examining the onset and duration of measured changes in discomfort.

Research contributes to the broader evidence landscape, focusing on short-term changes measured in outcomes related to physical discomfort during periods of increased symptom activity. However, the evidence is limited, as the research is primarily constrained to single-dose or very short-course usage in controlled settings.

Evidence for Use in Chronic Pain Conditions

The research base for chronic, moderate to moderately severe pain, such as that related to osteoarthritis (OA) and chronic low back pain (LBP), stems from intermediate-term Randomized Controlled Trials (RCTs) and large systematic reviews. These studies explored patients who were experiencing conditions marked by functional limitations and where symptoms may vary in intensity.

Studies evaluated outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings describe group patterns related to how patients reported their experience and how outcomes reflecting daily functioning or activity level were measured in the observed populations.

Gaps and Uncertainty in the Research Record

A primary limitation is the lack of long-term data for chronic use, as controlled trials were not designed to monitor outcomes beyond the 12-week mark. Regulatory documentation explicitly states that the combination has not been systematically evaluated beyond 12 weeks in controlled settings. Furthermore, data for certain groups remain insufficient, including populations such as children or pregnant populations, as these groups are often excluded from initial controlled trials. Research does not determine whether an individual will respond similarly.

Key Studies & References

1. Official ULTRACET Label (Tramadol and Acetaminophen) - Product Labeling via NIH DailyMed

Common questions about Ultracet (FAQ)

Q: What is Ultracet used for?

A: Ultracet is approved for the short-term (five days or less) management of acute pain that is severe enough to require an opioid treatment and for which alternative treatments are inadequate. It is a combination medication containing tramadol (an opioid) and acetaminophen (a non-opioid pain reliever).

Q: Is Ultracet a controlled substance?

A: Yes, tramadol, one of the active ingredients in Ultracet, is classified as a Schedule IV controlled substance due to its potential for abuse, dependence, and misuse. The combination product, Ultracet, is therefore also subject to controlled substance regulations.

Q: How should I stop taking Ultracet?

A: Discontinuing any medication, especially one containing an opioid, should be done under the guidance of a healthcare professional. Suddenly stopping treatment may lead to withdrawal symptoms in individuals who have developed physical dependence. A doctor may recommend a gradual reduction in dosage to minimize these effects.

Q: Can I take other pain relievers with Ultracet?

A: It is important to check with a healthcare provider or pharmacist before taking any other pain relievers. Ultracet already contains acetaminophen, and taking additional products that also contain acetaminophen could lead to an accidental overdose and liver damage.

Q: What are the most common side effects of Ultracet?

A: The drug’s label indicates that common side effects may include dizziness, somnolence (drowsiness), nausea, vomiting, constipation, and headache. It is advisable to discuss the potential risks and benefits with a prescribing healthcare professional.

Official Storage and Handling

ULTRACET tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted from 15 C to 30 C [1.2]. Storage environments must avoid excess heat and moisture and protect the tablets from freezing or direct light [1.3]. The medication should remain in its original container and be kept tightly closed [1.3].

Child-Safety Storage

Due to the presence of an opioid component, it is mandatory to store the product out of the sight and reach of children and in a safe, secure place to prevent accidental ingestion or misuse [1.3].

Disposal Requirements

Expired or unused ULTRACET must be promptly disposed of [1.4]. The preferred method is using an authorized Drug Take-Back Program or DEA-registered collector [2.7]. If a take-back option is unavailable, disposal can occur in the household trash by removing the tablets from their container, mixing them with an undesirable substance like used coffee grounds or dirt, and placing the mixture in a sealed bag [2.3]. The product is not on the FDA's flush list [2.7].